Day Lewis has seen pre-tax losses of more than £4 million in 2024/25 despite a growth in sales, company accounts for the year ending March 31 2025 have revealed.
Published on Companies House earlier this month (October 9), the document showed that the UK’s “second-largest independent pharmacy chain” saw pre-tax losses hit £4.06m in 2025, down from a pre-tax profit of £7.97m the year before.
Read more: Day Lewis: Pharmacy doesn’t need ‘new contract’ but ‘tweaks’
This represents a drop in profits of just over £12m, or 151%.
However, sales increased to £506.8m over the same period, compared to £502.1m last year, it said.
And a representative yesterday (October 22) stressed that the chain “remains financially secure”.
“Enhanced estate”
According to the filing, Day Lewis owns or manages 245 pharmacies across England as of March 31 this year.
The company said that it was continuing to “enhance [its] estate through relocating branches to superior locations, focusing on added value services, merging multiple pharmacies into larger single sites and disposing of pharmacies with particularly low footfall”.
Read more: Rowlands back in the black after £600k profit
It added that one area of focus for the company is “24/7 prescription collection kiosks”, with 99 installed across its pharmacies this year, up from 77 in 2024.
Another “core” focus area is hub-and-spoke dispensing automation, which Day Lewis said it continues to invest in “to streamline operations, improve efficiency and support future scalability”.
Read more: Family-run London chain’s losses up 272% despite turnover growth
The company also revealed that its administrative expenses have increased by 7% to £120.5m for 2024/25.
Most of these expenses are “linked to headline inflation rates such as staff costs, energy, utilities and rent and rates”, it said.
“Financially secure”
Day Lewis told C+D that it “remains financially secure” and that its “underlying performance in 2024/25” is “in line with previous years”.
It added that the company’s accounts were “adversely impacted by a one-off non-cash impairment” that it said “reflects the wider funding pressures facing community pharmacy”.
The company declined to comment on what exactly the non-cash impairment refers to but stressed that the “challenges urgently require government attention”.
Read more: Peak Pharmacy losses up 42% despite ‘large-scale automation’
It comes after a Companies House filing revealed that Rowlands has seen pre-tax profits increase by 102%, rising from a loss of £37.9m in 2023/24 to a profit of £637k in 2024/25.
The company accounts for the year ending January 31 2025, published earlier this month, also showed that the company’s turnover rose by 27%, jumping from £410m in the year ending January 31 2024 to £522.5m at the end of this January.
